Algeria Key takeaways
- Modern breast cancer care increasingly depends on biomarkers and molecular testing.
- The 2026 Algerian guidelines incorporate several of these advances into national treatment pathways.
- Diagnostic capacity and treatment availability are both essential for implementing precision oncology.
- Multidisciplinary RCPs can help integrate biology, treatment response and real-world access into individual decisions.
Breast cancer treatment is changing rapidly. Immunotherapy, antibody–drug conjugates, targeted therapies and molecular testing are progressively changing how treatment decisions are made.
In Algeria, the challenge in 2026 is therefore no longer only to know what the international evidence recommends.
It is also to ask:
Can the patient in front of us access the diagnostic test and treatment required to implement that recommendation?
From treatment to treatment pathways
Modern breast oncology increasingly depends on a sequence of decisions.
In triple-negative breast cancer, treatment decisions may involve immunotherapy and germline BRCA testing, while PD-L1 assessment is particularly relevant in the metastatic setting. A patient with HER2-positive disease requires reliable HER2 testing and access to anti-HER2 treatment. In metastatic HR-positive disease, molecular alterations such as ESR1 or PIK3CA may increasingly influence treatment selection.
The treatment decision is therefore only one part of the pathway.
Biomarker → test → RCP → treatment → monitoring
If one link is missing, precision oncology becomes difficult to implement.
The Algerian 2026 framework
The updated Algerian therapeutic guidelines reflect many of these changes, incorporating immunotherapy, targeted therapies, anti-HER2 strategies and molecularly guided approaches across breast cancer subtypes. This is an important step. But national recommendations and real-world implementation are not necessarily the same thing.
The availability of a test may vary between institutions. Access to molecular testing may depend on where the patient is treated. Some innovative treatments may be available within the national system but not necessarily in every centre or at every point in the patient’s treatment journey.
For the oncologist, this creates a practical challenge:
How do we translate the guideline into the best achievable pathway for an individual patient?
The RCP has a central role
This is where the multidisciplinary RCP becomes particularly important.
The discussion is no longer limited to stage and histology. It increasingly includes:
- molecular and biomarker results;
- pathological response after neoadjuvant treatment;
- previous systemic therapies;
- comorbidities;
- potential clinical trial opportunities;
- and, inevitably, treatment availability.
This does not mean lowering the therapeutic ambition.
It means identifying what is required to deliver evidence-based care and, when a barrier exists, making that barrier visible.
The next step is implementation
Algeria has made important progress in incorporating modern breast cancer strategies into its 2026 therapeutic framework.
The next challenge is ensuring that diagnostic capacity, treatment availability and multidisciplinary expertise evolve together. A new drug cannot transform outcomes if the biomarker needed to select the patient is unavailable. A sophisticated molecular test has limited clinical value if its result does not lead to an accessible treatment. And a guideline can only change practice when it can be translated into a reproducible pathway across centres. For breast cancer in Algeria, the question in 2026 is therefore not simply whether modern therapies exist. It is whether we can increasingly make the right test, for the right patient, at the right time, lead to the right treatment.
